Tirzepatide: research protocol, dosing & reconstitution
Also known as: Mounjaro (brand), Zepbound (brand)
Quick answer
What is Tirzepatide?
Tirzepatide is a dual-hormone compound that activates both the GLP-1 and GIP receptors — two gut-hormone pathways involved in appetite and blood sugar. It is the active ingredient in Mounjaro and Zepbound, and produced the largest weight reductions of any approved medication in its trials.
What Tirzepatide is
Tirzepatide is a single molecule engineered to activate two receptorsReceptorA protein on or inside a cell that binds specific signaling molecules and triggers a response. Most peptides work by binding particular receptors.See glossary → at once: GLP-1GLP-1 (glucagon-like peptide-1)A gut hormone that stimulates insulin release, slows stomach emptying, and reduces appetite. GLP-1 receptor agonists such as semaglutide are studied and prescribed for metabolic regulation.See glossary → (like semaglutide) plus GIP (glucose-dependent insulinotropic polypeptide). The dual action is why trial results exceeded GLP-1-only compounds.
In Canada it is a prescription drug (Mounjaro, Zepbound). Research vendors sell lyophilizedLyophilizedFreeze-dried. Peptides are shipped as a lyophilized powder ('puck') because the dry form is far more stable than a solution. It must be reconstituted before use in research.See glossary → tirzepatide — commonly 5 mg, 10 mg, or 15 mg vialsVialThe small sealed glass container peptides are supplied in, topped with a rubber septum that a syringe needle can pass through.See glossary → — strictly as Research Use OnlyRUO (Research Use Only)A regulatory classification meaning a product is sold strictly for laboratory research and is not approved, labeled, or intended for human or veterinary use.See glossary →.
Mechanism of action
GLP-1 receptor activation suppresses appetite, slows gastric emptying, and improves insulin response; adding GIP receptor activation appears to enhance insulin sensitivity and may blunt some GI side effects, allowing higher effective dosing. In the SURMOUNT-1 trial, participants on 15 mg weekly lost a mean of 20.9% of body weight over 72 weeks [1].
Head-to-head diabetes trials (SURPASS-2) reported greater A1C and weight reductions with tirzepatide than semaglutide 1 mg [2].
What researchers study Tirzepatide for
- Weight management (largest effect size of approved incretins)
- Glycemic control in type 2 diabetes
- Insulin-sensitivity and dual-incretin mechanism studies
- Obstructive sleep apnea and cardiometabolic research
What dose of Tirzepatide do researchers use?
Research literature commonly references doses of Titrated: 2.5 mg/wk start → 5 → 7.5 → 10 → 12.5 → max 15 mg/wk. This is not a recommendation — the table below summarizes protocols as they appear in published literature and trial designs.
| Context | Dose | Frequency | Duration |
|---|---|---|---|
| Clinical titration reference (SURMOUNT/SURPASS) | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg | Once weekly, step up every 4 weeks | 20-week titration to top dose |
| Literature-referenced starting point | 2.5 mg | Once weekly | 4 weeks before first increase |
← Swipe to see the full table
Half-life and dosing timing
Half-life: ~5 days (once-weekly dosing). Route referenced in research: Subcutaneous, weekly. Half-lifeHalf-lifeHow long it takes for half of a compound to be eliminated from the body. Half-life determines how often researchers dose a compound in protocols.See glossary → is about 5 days — once-weekly dosing on a consistent day. Like semaglutide, each titrationTitrationStarting at a low dose and increasing gradually on a schedule. Research protocols titrate to assess tolerance — 'start low, go slow.'See glossary → step is held 4 weeks so levels stabilize before assessing tolerance.
Titration: start low, go slow
The trial schedule steps 2.5 mg at a time every 4 weeks. The 2.5 mg start is explicitly a tolerance dose, not a treatment dose. Slower escalation is the trial-documented answer to GI effects.
Skip the Tirzepatide math
Enter vial size, water volume, and target dose — the free calculator returns concentration, injection volume, and exact U-100 syringe units.
How is Tirzepatide reconstituted?
| Vial size | BAC water | Concentration | Worked example |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 2.5 mg = 0.5 mL = 50 units on a U-100 syringe |
| 15 mg | 3 mL | 5 mg/mL | 5 mg = 1 mL = 100 units (a full U-100 syringe) |
Add 2 mL of bacteriostatic waterBAC water (bacteriostatic water)Sterile water containing 0.9% benzyl alcohol, which suppresses bacterial growth. It is the standard diluent used to reconstitute lyophilized peptides for multi-dose research vials.See glossary → to a 10 mg vial: 10 ÷ 2 = 5 mg/mL. A 2.5 mg starting dose is 2.5 ÷ 5 = 0.5 mL — 50 units on a U-100 syringeU-100 syringeAn insulin syringe calibrated so that 100 units equal 1 mL. The standard syringe referenced in peptide research; each unit equals 0.01 mL.See glossary →.
New to the process? Read the full step-by-step reconstitution guide.
How long does reconstituted Tirzepatide last?
Lyophilized: refrigerate. ReconstitutedReconstitutionThe process of mixing a freeze-dried (lyophilized) peptide powder with bacteriostatic water to create a solution of known concentration.See glossary →: refrigerate at 2–8°C and use within weeks; keep from light and do not freeze the solution.
What is Tirzepatide stacked with in research?
Run solo in research protocols. Its dual mechanism is itself the 'stackPeptide stackTwo or more peptides used together in a research protocol because their mechanisms are complementary — for example, BPC-157 with TB-500.See glossary →' — trial literature manages tolerance through titration speed, not added compounds.
Side effects observed in research
Trial-documented effects are mostly gastrointestinal — nausea, vomiting, diarrhea, reduced appetite — typically during dose escalation. Class-level cautions (pancreatitis, gallbladder disease, thyroid C-cell findings in rodents) apply.
- Nausea
- Vomiting
- Diarrhea
- Appetite loss
Frequently asked questions
How is tirzepatide different from semaglutide?
Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates GLP-1 only. In trials, tirzepatide produced greater average weight loss (20.9% at 15 mg in SURMOUNT-1 vs 14.9% for semaglutide 2.4 mg in STEP 1 — different trials, not head-to-head for weight).
What is the tirzepatide titration schedule?
Trials started at 2.5 mg weekly and increased by 2.5 mg every 4 weeks to a maximum of 15 mg — a 20-week climb.
Is research tirzepatide the same as Mounjaro?
No. Mounjaro is a regulated pharmaceutical. Research-vendor tirzepatide is a Research Use Only chemical whose quality depends entirely on vendor testing and COA documentation.
Why does tirzepatide cause nausea?
GLP-1 receptor activation slows stomach emptying. Nausea clusters around dose increases and typically settles as tolerance develops — the reason trial titration is slow.
Related research peptides
Semaglutide
A GLP-1 receptor agonist studied and prescribed for glycemic control and weight management.
GLP-1 / MetabolicRetatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) showing the largest weight-loss figures of the class in Phase 2 trials (~24% at 48 weeks, 12 mg).
Healing & RecoveryBPC-157
A synthetic peptide fragment studied for tissue repair, tendon/ligament and gut healing in animal research.
Browse all GLP-1 / Metabolic peptides or start with the beginner’s guide to research peptides.